Received Aug 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
HCP confirmed he was not aware of any symptomatic side effects from the first two doses of GARDASIL-9.; Inbound call from pharmacist calling to inquire if a patient can still receive a 3rd dose of GARDASIL-9 after having his series interrupted. Caller states that patient received his first dose on 10-JUN-2024 and his 2nd dose on 9-SEP-2024. HCP did n; This spontaneous report was received from pharmacist and refers to a male patient of unknown age. The patient's medical history, historical drugs, known drug allergies, concurrent conditions, and concomitant therapies were not reported. On 10-Jun-2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), suspension for injection, 1 dosage form (anatomical location, route of administration, lot # and expiration date were not reported), as prophylaxis. On 09-Sep-2024, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), suspension for injection, 1 dosage form (anatomical location, route of administration, lot # and expiration date were not reported), as prophylaxis. Then on 20-AUG-2025, the pharmacist inquired if the patient could still receive the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) after having his series interrupted. The pharmacist did not know why the patient had delayed his 3rd dose and he was not aware of any symptomatic side effects from the first two doses of the vaccine. Lot # is being requested and will be submitted if received.